Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Dabrafenib in patients with Melanoma.

Statements

Source and description
Tafinlar (dabrafenib) [product information]. EMA. The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult and adolescent patients aged 12 years and older with unresectable or metastatic melanoma with a BRAF V600 variant.